ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 633 DKK | +2.51% |
|
+8.86% | +69.61% |
| 04/04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| 20/03 | Zealand Pharma A/S Approves Appointments to the Board | CI |
ETFs positioned on Zealand Pharma A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +1.51% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -3.23% | - | |
| 0.00% | 152 M€ | -3.45% | - | |
| 0.00% | 26 M€ | -4.26% | - |
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
16/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
633
DKK
Average target price
782
DKK
Spread / Average Target
+23.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +69.61% | 5.65B | |
| -3.46% | 102B | |
| +1.41% | 96.09B | |
| +2.13% | 22.28B | |
| -15.84% | 21.4B | |
| -9.21% | 18.14B | |
| -39.98% | 17.02B | |
| -14.65% | 16.09B | |
| +4.39% | 13.83B | |
| +31.35% | 11.97B |
- Stock Market
- Equities
- ZEAL Stock
- Funds and ETFs Zealand Pharma A/S
